Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Researchers want to find the best dose of ADCLEC.syn1 that can be used in people with leukemia. The people in this study have acute myeloid leukemia (AML) that keeps growing even after treatment. There are currently no FDA-approved CAR T cell therapies for AML.
Researchers want to see if combining etentamig (ABBV-383) with iberdomide is a safe treatment for multiple myeloma. The people in this study have multiple myeloma that came back or keeps growing after treatment. The researchers will assess different doses of these drugs to find the best dose for patients.
Researchers want to see how well the drug enasidenib works in people with angioimmunoblastic T-cell lymphoma (AITL). The people in this study have AITL that came back or keeps growing after treatment. Their cancers also have a mutation (change) in the IDH2 gene.
Researchers want to see if ruxolitinib works well as a treatment for T-cell large granular lymphocytic leukemia (T-LGLL). T-LGLL is a rare cancer of white blood cells called lymphocytes. The people in this study have T-LGLL that keeps growing even with treatment.
Researchers want to find the best dose of TORL-1-23 to use in people with advanced solid tumors. The people in this study have solid tumors that have spread and cannot be successfully treated with standard therapies.
Multiple myeloma that keeps growing after treatment can cause cancer cells to build up inside the bones. The cancer cells crowd out healthy blood cells and make abnormal proteins that cause discomfort. Researchers in this study want to find the best dose of KTX-1001 to treat multiple myeloma that grows after treatment.
In this study, researchers want to see if adding stereotactic body radiation therapy (SBRT) to standard drug therapy is effective for people with estrogen receptor (ER)-positive HER2-positive oligometastatic breast cancer that has gotten worse at one metastatic site despite medical treatment. Oligometastatic breast cancer is cancer that has spread to a small number of parts of the body. SBRT delivers extremely precise, very intense doses of radiation to cancer cells.
CAR T-cell therapy is a type of immunotherapy used to treat some people with lymphoma that has continued to grow despite prior treatment. The treatment involves using a patient's own T cells (a type of white blood cell), genetically modifying them in the laboratory to recognize a protein on cancer cells, and multiplying them. The modified T cells, known as CAR T cells, are then returned to the patient to find and kill cancer cells throughout the body.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
